Prognostic significance of hepatoma-up-regulated protein expression in patients with urinary bladder transitional cell carcinoma

Anticancer Research

Volumn 23, Issue 3 B, 2003, Pages 2729-2733

  Huang, Yu Lun ^a   Chiu, Allen W ^a,b   Huan, Steven K ^a   Wang, Yu Chun ^a   Ju, Jyh Phen ^a   Lu, Chin Li ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

HURP; Prognosis; Recurrence; Transitional cell carcinoma; Urinary bladder

Indexed keywords

CYTOKERATIN; MOLECULAR MARKER; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER INVASION; DNA CONTENT; FEMALE; HEPATOMA UPREGULATED PROTEIN; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; TISSUE DISTRIBUTION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR LOCALIZATION; TUMOR RECURRENCE; UROTHELIUM;

AGED; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0041805499     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Koenig F, Jung K, Schnorr D and Loening S: Urinary markers of malignancy. Clinica Chimica Acta 297: 191-205, 2000.
2. Rubben H, Lutzeyer W, Fischer N, Deutz F, Agrange W and Giani G: Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139: 283-285, 1988.
3. Droller M: Individualizing the approach to invasive bladder cancer. Contemp Urology July/August: 54-61, 1990.
4. Bittard H, Lamy B and Billerey C: Clinical evaluation of cell deoxyribonucleic acid content measured by flow cytometry in bladder cancer. J Urol 155: 1887-1891, 1996.
5. Droller M: Bladder cancer: state-of-the -art care. CA Cancer J Clin 48: 269-284, 1998.
6. Sarosdy M; deVere W, Soloway M, Sheinfeld J, Hudson M, Schellhammer P, Jarowenko M, Adams G and Blumenstein B: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154: 379-384, 1995.
7. Senga Y, Kimura G, Hattori T and Yoshida K: Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer. Urology 48: 703-710, 1996.
8. Harnden P, Eardley I, Joyce A and Southgate J: Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 78: 870-875, 1996.
9. Soloway M, Briggman V, Carpinito G, Chodak G, Church P, Lamm D, Lange P, Messing E, Pasciak R, Reservitz G, Rukstalis D, Sarosdy M, Stadler W, Thiel R and Hayden C: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156: 363-367, 1996.
10. Stampfer D, Carpinito G, Rodriguez-Villanueva J, Willsey L, Dinney C, Grossman H, Fritsche H and McDougal W: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 159: 394-398, 1998.
11. Jayachandran S, Mooppan MU, Wax S and Kim H: The value of urinary fibrin/fibrinogen degradation products as tumor markers in urothelial carcinoma. J Urol 132: 21-23, 1984.
12. Kavaler E, Landman J, Chang Y, Droller M and Liu B: Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 82: 708-714, 1998.
13. Chiu A, Huang Y, Huan S, Wang Y, Ju J, Chen M and Chou C: Potential molecular marker for detecting transitional cell carcinoma. Urology 60: 181-185, 2002.
14. Annual Report of Statistical Abstract by Cause of Death. Taiwan, ROC, Department of Health, 2001.
15. Chen C, Kuo T and Wu M: Arsenic and cancers. Lancet 20: 414-415, 1988.
16. Wu M, Kuo T, Hwang Y and Chen C: Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 130: 1123-1131, 1989.
17. Chen C, Chuang Y, Lin T and Wu H: Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45: 5895-5899, 1985.
18. Chiang H, Guo H, Hong C, Lin S and Lee E: The incidence of bladder cancer in the black foot disease endemic area in Taiwan. Br J Urol 71: 274-278, 1993.
19. Epstein J, Amin M, Reuter V and Mostofi F: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435-1448, 1998.
20. Chisholm G, Hindmarsh J, Howatson A, Webb J, Busuttil A, Hargreave T and Newsam J: TNM (1978) in bladder cancer: use and abuse. Br J Urol 52: 500-505, 1980.
21. Chiang H, Hong C, Guo H, Lee E and Chen T: Comparative study on the high prevalence of bladder cancer in the blackfoot disease endemic area in Taiwan. Taiwan Yi Xue Hui Za Zhi 87: 1074-1080, 1988.
22. Nomura N, Miyajima N, Sazuka T, Tanaka A, Kawarabayasi Y, Sato S, Nagase T, Seki N, Ishikawa K and Tabata S: Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1. DNA Res 1: 27-35, 1994.
23. Bassal S, Nomura N, Venter D, Brand K, McKay M and Spek Pvd: Characterization of a novel human cell-cycle-regulated homologue of Drosophila dlg1. Genomics 77: 5-7, 2001.
24. Ro J, Staerkel G and Ayala A: Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 19: 435-453, 1992.
25. Heney N: Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 19: 429-433, 1992.
26. Badalament RA and Burgers JK: Recurrent or aggressive bladder cancer. Indications for adjuvant intravesical therapy. Urol Clin North Am 19: 485-498, 1992.
27. Raghavan D, Shipley W, Garnick M, Russell P and Richie J: Biology and management of bladder cancer. N Engl J Med 322: 1129-1138, 1990.
28. Stein J, Grossfeld G, Ginsberg D, Esrig D, Freeman J, Figueroa A, Skinner D and Cote R: Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 160: 645-659, 1998.